{"id":"https://openalex.org/W7224999937","doi":"https://doi.org/10.1002/bcp.70900","title":"Dosing HIV integrase inhibitors with enzyme inducers: Convenience vs . control?","display_name":"Dosing HIV integrase inhibitors with enzyme inducers: Convenience vs . control?","publication_year":2026,"publication_date":"2026-10-30","ids":{"openalex":"https://openalex.org/W7224999937","doi":"https://doi.org/10.1002/bcp.70900","pmid":"https://pubmed.ncbi.nlm.nih.gov/42963934"},"language":"en","primary_location":{"id":"doi:10.1002/bcp.70900","doi":"https://doi.org/10.1002/bcp.70900","is_oa":true,"landing_page_url":"https://doi.org/10.1002/bcp.70900","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70900","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70900","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047434629","display_name":"Catia Marzolini","orcid":"https://orcid.org/0000-0002-2312-7050","observed_orcids":["https://orcid.org/0000-0002-2312-7050"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]},{"id":"https://openalex.org/I1850255","display_name":"University of Basel","ror":"https://ror.org/02s6k3f65","country_code":"CH","type":"education","lineage":["https://openalex.org/I1850255"]},{"id":"https://openalex.org/I2802229882","display_name":"Centre Hospitalier Universitaire Vaudois","ror":"https://ror.org/05a353079","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802229882"]},{"id":"https://openalex.org/I2802542264","display_name":"University Hospital of Basel","ror":"https://ror.org/04k51q396","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802542264"]},{"id":"https://openalex.org/I97565354","display_name":"University of Lausanne","ror":"https://ror.org/019whta54","country_code":"CH","type":"education","lineage":["https://openalex.org/I97565354"]}],"countries":["CH","GB"],"is_corresponding":true,"raw_author_name":"Catia Marzolini","raw_affiliation_strings":["Centre for Experimental Therapeutics University of Liverpool  Liverpool UK","Division of Infectious Diseases University Hospital Basel and University of Basel  Basel Switzerland","Service of Clinical Pharmacology University Hospital Lausanne and University of Lausanne  Lausanne Switzerland"],"raw_orcid":"https://orcid.org/0000-0002-2312-7050","affiliations":[{"raw_affiliation_string":"Centre for Experimental Therapeutics University of Liverpool  Liverpool UK","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Division of Infectious Diseases University Hospital Basel and University of Basel  Basel Switzerland","institution_ids":["https://openalex.org/I1850255","https://openalex.org/I2802542264"]},{"raw_affiliation_string":"Service of Clinical Pharmacology University Hospital Lausanne and University of Lausanne  Lausanne Switzerland","institution_ids":["https://openalex.org/I2802229882","https://openalex.org/I97565354"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041365930","display_name":"Saye Khoo","orcid":"https://orcid.org/0000-0002-2769-0967","observed_orcids":["https://orcid.org/0000-0002-2769-0967"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Saye Khoo","raw_affiliation_strings":["Centre for Experimental Therapeutics University of Liverpool  Liverpool UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Experimental Therapeutics University of Liverpool  Liverpool UK","institution_ids":["https://openalex.org/I146655781"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5047434629"],"corresponding_institution_ids":["https://openalex.org/I146655781","https://openalex.org/I1850255","https://openalex.org/I2802229882","https://openalex.org/I2802542264","https://openalex.org/I97565354"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":{"value":4780,"currency":"USD","value_usd":4780},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.85509542,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-integrase-inhibitors","display_name":"HIV integrase inhibitors","score":0.8299999833106995},{"id":"https://openalex.org/keywords/dolutegravir","display_name":"dolutegravir","score":0.9919999837875366},{"id":"https://openalex.org/keywords/bictegravir","display_name":"bictegravir","score":1.0},{"id":"https://openalex.org/keywords/enzyme-inducers","display_name":"enzyme inducers","score":0.9440000057220459},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7829999923706055},{"id":"https://openalex.org/keywords/pharmacokinetic-interactions","display_name":"pharmacokinetic interactions","score":0.8169999718666077},{"id":"https://openalex.org/keywords/ugt1a1","display_name":"UGT1A1","score":0.9020000100135803},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.9980000257492065},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":0.8830000162124634},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.9070000052452087},{"id":"https://openalex.org/keywords/twice-daily-dosing","display_name":"twice-daily dosing","score":0.9670000076293945},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.8709999918937683},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6349999904632568},{"id":"https://openalex.org/keywords/adherence","display_name":"adherence","score":0.492000013589859},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.7160000205039978},{"id":"https://openalex.org/keywords/cftr-modulators","display_name":"CFTR modulators","score":0.8289999961853027},{"id":"https://openalex.org/keywords/hypericum-perforatum","display_name":"Hypericum perforatum","score":0.9819999933242798}],"concepts":[{"id":"https://openalex.org/C2779502633","wikidata":"https://www.wikidata.org/wiki/Q937224","display_name":"Dolutegravir","level":5,"score":0.8705000281333923},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7623999714851379},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7146000266075134},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6126000285148621},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5115000009536743},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5105999708175659},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.4214000105857849},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.362199991941452},{"id":"https://openalex.org/C2777302000","wikidata":"https://www.wikidata.org/wiki/Q412251","display_name":"Integrase inhibitor","level":5,"score":0.35910001397132874},{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.35600000619888306},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3431999981403351},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.3424000144004822},{"id":"https://openalex.org/C2779778239","wikidata":"https://www.wikidata.org/wiki/Q422604","display_name":"Emtricitabine","level":5,"score":0.2802000045776367},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.2671000063419342},{"id":"https://openalex.org/C2778607973","wikidata":"https://www.wikidata.org/wiki/Q422652","display_name":"Rifampicin","level":3,"score":0.2531999945640564}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1002/bcp.70900","doi":"https://doi.org/10.1002/bcp.70900","is_oa":true,"landing_page_url":"https://doi.org/10.1002/bcp.70900","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70900","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:42963934","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42963934","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/bcp.70900","doi":"https://doi.org/10.1002/bcp.70900","is_oa":true,"landing_page_url":"https://doi.org/10.1002/bcp.70900","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70900","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7224999937.pdf","grobid_xml":"https://content.openalex.org/works/W7224999937.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W1990069515","https://openalex.org/W2098185748","https://openalex.org/W2144255757","https://openalex.org/W2160104000","https://openalex.org/W2364684143","https://openalex.org/W2962927125","https://openalex.org/W3133643949","https://openalex.org/W3134682517","https://openalex.org/W4377292587","https://openalex.org/W4383721107","https://openalex.org/W4386020083","https://openalex.org/W4387729238","https://openalex.org/W4417076775","https://openalex.org/W7117567215","https://openalex.org/W7155020447"],"related_works":["https://openalex.org/W2029701369","https://openalex.org/W2588644807","https://openalex.org/W2012607545","https://openalex.org/W2064678175","https://openalex.org/W2738136433","https://openalex.org/W3028663891","https://openalex.org/W3195482978","https://openalex.org/W7218124332","https://openalex.org/W4214846980","https://openalex.org/W4409466161"],"abstract_inverted_index":{"Dolutegravir":[0],"and":[1,29,78,99,108,118,128,137,150,172,198],"bictegravir,":[2],"both":[3,39,76],"second-generation":[4],"integrase":[5],"strand":[6],"transfer":[7],"inhibitors":[8],"(INSTIs),":[9],"are":[10,41],"widely":[11],"used":[12],"as":[13,90],"key":[14],"components":[15],"of":[16,50,86,144,155,183],"antiretroviral":[17],"therapy":[18],"(ART)":[19],"because":[20],"they":[21],"combine":[22],"strong":[23,48,84],"antiviral":[24],"activity":[25],"with":[26,47,63,170],"good":[27],"tolerability":[28],"a":[30,68,81,189],"low":[31],"potential":[32],"for":[33,191],"drug-drug":[34],"interactions":[35],"(DDIs).":[36],"1":[37],"However,":[38],"agents":[40],"vulnerable":[42],"to":[43,80,134],"pharmacokinetic":[44],"interactions,":[45],"notably":[46],"inducers":[49,85,140],"their":[51],"metabolic":[52],"pathways.Dolutegravir":[53],"is":[54],"metabolized":[55],"predominantly":[56],"by":[57],"uridine":[58],"diphosphate":[59],"glucuronosyltransferase":[60],"(UGT)":[61],"1A1,":[62],"cytochrome":[64],"(CYP)":[65],"3A4":[66],"playing":[67],"minor":[69],"role,":[70],"whereas":[71],"bictegravir":[72,129,175],"undergoes":[73],"metabolism":[74],"through":[75],"UGT1A1":[77],"CYP3A4":[79],"similar":[82],"extent.Consequently,":[83],"these":[87,184,204],"enzymes,":[88],"such":[89],"rifamycins,":[91],"antiepileptic":[92],"drugs":[93,102],"(e.g.,":[94,103,116],"carbamazepine,":[95],"cenobamate,":[96],"phenobarbital,":[97],"phenytoin":[98],"primidone),":[100],"cancer":[101],"apatulamide,":[104],"dabrafenib,":[105],"enzalutamide,":[106],"ivosidenib":[107],"mitotane),":[109],"cystic":[110],"fibrosis":[111],"transmembrane":[112],"conductance":[113],"(CFTR)":[114],"modulators":[115],"ivacaftor":[117],"lumacaftor)":[119],"or":[120],"St":[121],"John's":[122],"wort,":[123],"can":[124,176],"substantially":[125],"reduce":[126],"dolutegravir":[127,165],"concentrations,":[130],"which":[131,146,203],"may":[132,147],"lead":[133],"treatment":[135],"failure":[136],"resistances.2":[138],"Strong":[139],"require":[141],"twice-daily":[142,174],"dosing":[143,186,206],"dolutegravir,":[145],"compromise":[148],"adherence,":[149],"currently":[151],"preclude":[152],"the":[153,195],"use":[154],"bictegravir.2":[156],"Randomized":[157],"clinical":[158,181,200],"trials":[159],"have":[160],"therefore":[161],"investigated":[162],"whether":[163,173],"oncedaily":[164],"retains":[166],"efficacy":[167],"when":[168],"coadministered":[169],"rifampicin":[171,178],"overcome":[177],"induction.3,4":[179],"The":[180],"appropriateness":[182],"alternative":[185,205],"strategies":[187,207],"remains":[188],"matter":[190],"debate.This":[192],"commentary":[193],"reviews":[194],"available":[196],"evidence":[197],"discusses":[199],"situations":[201],"in":[202],"should":[208],"be":[209],"avoided.":[210]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-11-01T00:00:00"}